Loading…

Ardelyx, Inc.ARDXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum weak 20
Mkt cap
$784M
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$14.9M
20-day average traded
Fwd P/E
252.9×
forward earnings
ROIC−WACC
-29.3 pp
WACC 8.1%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$3.12
1D-1.9%
1W-0.3%
1M-2.8%
3M-20.0%
6M-50.2%
YTD-46.5%
1Y-47.2%
ATR %4.9%
Beta0.87
52w lowhigh62.9% off high

What Ardelyx does

Employees: 489

Ardelyx at a glance

Size Ardelyx (ARDX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $784M, the 2385th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.12 on 18 Nov 2026.

Performance Over six months the shares fell 50.2%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 19 in its peer set.

Growth Revenue grew 17.6% over the last twelve months (peer median +5.2%); the operating margin is -7.7% (peer median 12.0%).

Valuation It trades at 252.9× forward earnings against a peer median of 10.8× (most expensive of 8).

Capital Return on invested capital runs 29.3 points below its cost of capital (8.1% WACC).

Short interest Short interest is 11.6% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 97ARDX 49
Six months, rebased to 100: Ardelyx against the median of its 20 peers (local-currency closes).

Ardelyx financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$468M$407M$334M$124M$52.2M
Revenue growth—+22%+168%+139%—
Gross profit$439M$365M$281M$105M$43.4M
EBITDA-$33.0M-$37.9M-$25.9M-$62.0M-$59.2M
Net income-$55.5M-$61.6M-$39.1M-$66.1M-$67.2M
Free cash flow-$16.0M-$44.0M-$45.8M-$90.1M-$70.1M
Capital expenditure$443,000$1.49M$1.01M$344,000$55,000
Total debt$256M$208M$153M$56.0M$47.7M

Quarterly statements and history in the cockpit →

Ardelyx competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%002349000411BLISSGVSIRWDGUDORICSANOFI002390RIGL688073LXRXSUVEN30010024240029072171ARDX6-month return →1-month return →
Up and to the right = strong over both horizons. Ardelyx is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×100×200×IRWDGUDSANOFIRIGL688073COLL6078ARDXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ardelyx is the large dot.

Ardelyx competitors and peer comparison

How Ardelyx compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ardelyx against its 20 peers (data as of 18 Nov 2026)
MeasureARDXPeer medianRank in peer set
1-month return-2.8%-1.0%10th highest of 19
6-month return-50.2%-4.7%lowest of 19
Distance from 52-week high-62.9%-31.2%2nd lowest of 19
Revenue growth (TTM)+17.6%+5.2%6th highest of 19
Operating margin-7.7%12.0%4th lowest of 19
Forward P/E252.9×10.8×most expensive of 8
ROIC minus cost of capital-29.3 pp+0.5 pp3rd lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ardelyx ARDXUnited States$784M-50%+18%-8%252.9×n/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%n/a-2.5%+2.6%
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%n/an/an/a
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%n/a33.9%+10.1%
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%3.5×n/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%42.2×6.6%+17.7%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%19.6×16.3%-8.7%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%n/a-3.8%-0.8%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%10.8×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%24.3×13.9%+27.7%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%n/an/an/a
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%n/an/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%n/a0.3%+0.5%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%3.7×-2.6%+20.3%
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%10.4×4.6%+22.5%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%n/a13.5%-0.2%
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%n/a9.4%-1.4%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%n/an/an/a

Questions

Which companies are Ardelyx's closest peers?
The cockpit's peer set: Jinghua Pharmaceutical (002349.SZ), Zhejiang Int'l (000411.SZ), Sichuan Neautus Traditional Chinese (2206.HK), Bliss GVS Pharma (BLISSGVS.NS), Bambusa Therapeutics (BBTX), Ironwood Pharmaceuticals (IRWD), Knight Therapeutics (GUD.TO), Oric Pharmaceuticals (ORIC).
Is Ardelyx expensive compared with its peers?
On forward p/e it trades at 252.9× against a peer median of 10.8×, most expensive of 8 in its peer set.
How has Ardelyx stock performed?
Over six months to 18 Nov 2026 the shares returned -50.2% against -4.7% for the median peer; over one year -47.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.